Avanafil Explained

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012[1] and by EMA on June 21, 2013.[2] Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand.[3] Metuchen Pharmaceuticals obtained exclusive rights within the United States.[4]

Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis.[5] Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes.[6] About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.[6]

Medical use

Avanafil is used to treat erectile dysfunction (ED).[7]

Adverse effects

Although avanafil is generally well tolerated, dose dependent adverse effects can occur. The most common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain. While it is also uncommon, there is a potential for visual disturbances to occur in patients.

Mechanism of action

Avanafil inhibits phosphodiesterase-5, preventing the degradation of cGMP.[8] [9] The increased levels of cGMP causes vasodilation, resulting in an increased blood flow in the penis. Avanafil's mechanism of action takes places once nitric oxide is released, in association with sexual stimulation.

Synthesis

Avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative:[10]

External links

Notes and References

  1. Web site: Stendra FDA Approval History . . Drugs.com . 6 March 2021.
  2. Web site: Spedra (avanafil) . European Medicines Agency . 17 April 2014.
  3. Web site: VIVUS Announces Avanafil Partnership With Menarini . Vivus Inc . https://web.archive.org/web/20151208155146/http://ir.vivus.com/releasedetail.cfm?ReleaseID=775706 . 2015-12-08 . dead .
  4. Web site: VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to Stendra . Vivus Inc . 3 October 2016 .
  5. Web site: avanafil, Spedra . Medicine Net . 17 April 2014 .
  6. Kyle JA, Brown DA, Hill JK . Avanafil for erectile dysfunction . The Annals of Pharmacotherapy . 47 . 10 . 1312–1320 . October 2013 . 24259695 . 10.1177/1060028013501989 . Sage Publishing . 6562049 .
  7. Burke RM, Evans JD . Avanafil for treatment of erectile dysfunction: review of its potential . Vascular Health and Risk Management . 8 . 517–523 . 2012 . 22973106 . 3433322 . 10.2147/VHRM.S26712 . free .
  8. Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, Kobayashi T, Kojima K, Yee S, Yamada Y, Kikkawa K, Omori K . 6 . Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction . The Journal of Urology . 188 . 2 . 668–674 . August 2012 . 22704456 . 10.1016/j.juro.2012.03.115 .
  9. Sanford M . Avanafil: A Review of Its Use in Patients with Erectile Dysfunction . Drugs & Aging . 30 . 10 . 853–62 . October 2013 . 23955441 . 10.1007/s40266-013-0112-x . 23558269 .
  10. US . 6797709 . Yamada K, Matsuki K, Omori K Kikkawa K . Aromatic nitrogen-containing 6-membered cyclic compounds . 11 December 2003 . Tanabe Seiyaku Co .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Avanafil".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.